AAN 2023 | Semaglutide associated with favorable headache outcomes in idiopathic intracranial hypertension

Nina Yakovlevna Riggins, MD, FAAN, University of California, San Francisco, CA, discusses the potential effects of certain medications on people with different types of headaches, particularly those with increased intracranial pressure headache. Currently, there is a need for additional medication options for those with elevated intracranial pressure, as current treatments are not always effective. Recent research on new medications has found that certain GLP-1 agonists, such as semaglutide, may have beneficial effects on intracranial hypertension due to their vasodilatory actions. Studies have shown positive outcomes in patients with intracranial hypertension, including better exercise tolerance, weight loss, and improved headache symptoms. Dr Riggins emphasizes the holistic approach taken in her clinic to help patients live healthier, more functional lives. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.